Cytokines in clinical cancer therapy.
Cytokines have been of much interest in clinical cancer therapy research over the past decade. One important advance during the past year has been the clear demonstration, in large prospective randomized studies, that granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor reduce the neutropenia-related morbidity of cancer therapy.
Oettgen
H F
HF
Memorial Sloan-Kettering Cancer Center, New York.
D000740:Anemia / Q000628:therapy; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D016207:Cytokines / Q000627:therapeutic use*; D004341:Drug Evaluation; D006410:Hematopoiesis / Q000187:drug effects; D016298:Hematopoietic Cell Growth Factors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D007372:Interferons / Q000494:pharmacology / Q000627:therapeutic use; D007378:Interleukins / Q000494:pharmacology / Q000627:therapeutic use; D009369:Neoplasms / Q000150:complications / Q000628:therapy*; D009503:Neutropenia / Q000209:etiology / Q000628:therapy
D000970:Antineoplastic Agents; D016207:Cytokines; D016298:Hematopoietic Cell Growth Factors; D007155:Immunologic Factors; D007378:Interleukins; D007372:Interferons